This study is not yet recruiting. It focuses on depression and currently lists study information in the United States.
This study is looking at whether Ketamine (0.25 mg/kg) can help people with Treatment Resistant Depression. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to Ketamine (0.25 mg/kg), but direct benefit is not guaranteed.
The official record suggests in-person participation through a university, with sites including Columbia University Irving Medical Center in New York. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis and having a stable enough treatment background for the study, while common reasons not to take part include active substance or alcohol problems that could affect the results and pregnancy or breastfeeding. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help clarify how this condition is measured or understood.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Soterix Medical. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.